MicroRNA-155 Expression has Prognostic Value in Patients with Non-small Cell Lung Cancer and Digestive System Carcinomas

Xu, Tongpeng; Zhu, Canhong; Zhang, Jian; Xia, Rui; Wu, Fenglei; Liang, Han; Shen, Hua; Liu, Lingxiang; Shu, Yongqian

doi:10.7314/apjcp.2013.14.12.7085

Cited by 34 publications

(24 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5,6 The association of ACE gene I/D polymorphism with cancer susceptibility has been widely evaluated; however the results are not often reproducible. 7,8 For instance, a previous study in a European population documented that ACE gene II genotype was significantly associated with a reduced risk of having gastric cancer relative to the DD genotype homozygotes, 9 and contrastingly carriers of II genotype were at an increased risk for gastric cancer in a Japanese population.…”

Section: Introductionmentioning

confidence: 99%

The relationship between angiotensin-converting enzyme gene insertion/deletion polymorphism and digestive cancer risk: Insights from a meta-analysis

Yang

Cai

et al. 2015

J Renin Angiotensin Aldosterone Syst

View full text Add to dashboard Cite

Background and objective: The gene encoding angiotensin-converting enzyme (ACE) has been implicated in the development of several malignancies. We aimed to meta-analyze the association of ACE gene insertion/deletion (I/D) polymorphism with digestive cancer risk and seek possible sources of between-study heterogeneity. Methods: Two authors independently assessed eligibility of each retrieved publication and gathered relevant data. Risk estimates were expressed as odds ratio (OR) and 95% confidence interval (CI). Results: Sixteen publications were qualified for analysis, involving 2903 digestive cancer cases and 10,833 controls. Overall analyses failed to show any significance for digestive cancer risk. There was moderate heterogeneity and lower publication bias for overall comparisons. In subgroup analyses, ACE gene II genotype was associated with a 15% reduced risk (OR=0.85, 95% CI: 0.57–1.27, p=0.434) for gastric cancer, but a 16% increased risk (OR=1.16, 95% CI: 0.89–1.52, p=0.273) for colorectal cancer. By source of controls, the I allele appeared to be a protective factor against digestive cancer in population-based studies (OR=0.87, 95% CI: 0.75–1.00, p=0.055) but a risk-conferring factor in hospital-based studies (OR=1.17, 95% CI: 1.01–1.35, p=0.033). Conclusion: Our findings suggested that ACE gene I allele might be a protective factor against gastric cancer, necessitating further confirmation in large, population-based studies.

show abstract

Section: Introductionmentioning

confidence: 99%

The relationship between angiotensin-converting enzyme gene insertion/deletion polymorphism and digestive cancer risk: Insights from a meta-analysis

Yang

Cai

et al. 2015

J Renin Angiotensin Aldosterone Syst

View full text Add to dashboard Cite

show abstract

“…Downregulation of global miRNAs can be found in tumors compared with normal tissues by miRNA expression profiling analysis which reveal the potential corelation of miRNAs and tumorigenesis (Lu et al, 2005;Thomsom et al, 2006;Xu et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

How to Explain the Contradiction of microRNA 200c Expression and Survival in Solid Tumors?: a Meta-analysis

Wang

Shen²,

Jiang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…The overexpression in C stage correlated with low chemotherapy sensitiveness and early recurrence (Schetter et al, 2008). Other studies about miR155 demonstrated that over-expression of miR-155 was markedly related to both OS (Overall Survival) and RFS/CSS (Recurrence-free Survival or Cancer-specific Survival) in patients with digestion system cancer (Xu et al, 2013). MiR29a was detected overexpressing in CRC patients with liver metastasis .…”

Section: Discussionmentioning

confidence: 90%

MicroRNAs as Promising Biomarkers for Tumor-staging: Evaluation of MiR21 MiR155 MiR29a and MiR92a in Predicting Tumor Stage of Rectal Cancer

Yang

Peng²,

Tang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Objective: In this study, tumor-stage predictive abilities of miR21, miR155, miR29a and miR92a were evaluated in rectal cancer (RC). Methods: Expression of miR21, miR155, miR29a and miR92a was detected and quantitated in tumor tissue and in adjacent normal tissue from 40 patients by TaqMan MicroRNA assay. Results: Significant overexpression of miR21, miR155, miR29a and miR92a was observed in RC tissues. While high expression of miR21, miR155 and miR29a in N1-2 and C-D stages presented a potential correlation with N and Duke stages, partial correlation analysis suggested that only miR155 rather than miR21 and miR29a played a greater influencing role. Receiver operating characteristics (ROC) curve analysis showed that miR155 could discriminate N0 from N1-2 with 85.0% sensitivity and 85.0% specificity, N2 from N0-1 with 90.0% sensitivity and 96.7% specificity, and C-D stage from A-B stage with 81.0% sensitivity and 84.2% specificity. Conclusions: Increase in expression of miR155 might represent a novel predictor for RC N and Dukes staging.

show abstract

MicroRNA-155 Expression has Prognostic Value in Patients with Non-small Cell Lung Cancer and Digestive System Carcinomas

Cited by 34 publications

References 39 publications

The relationship between angiotensin-converting enzyme gene insertion/deletion polymorphism and digestive cancer risk: Insights from a meta-analysis

The relationship between angiotensin-converting enzyme gene insertion/deletion polymorphism and digestive cancer risk: Insights from a meta-analysis

How to Explain the Contradiction of microRNA 200c Expression and Survival in Solid Tumors?: a Meta-analysis

MicroRNAs as Promising Biomarkers for Tumor-staging: Evaluation of MiR21 MiR155 MiR29a and MiR92a in Predicting Tumor Stage of Rectal Cancer

Contact Info

Product

Resources

About